ENTA

Enanta Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

10.820

-0.14(-1.277%)1D

Line

Candle

YTD

High

11.180

Open

10.920

VWAP

10.81

Vol

380.97K

Mkt Cap

301.64M

Low

10.440

Amount

4.12M

EV/EBITDA(TTM)

Total Shares

21.18M

102.78M

EV/OCF(TTM)

P/S(TTM)

3.60

Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. The Company’s clinical programs are focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including receptor tyrosine kinase (KIT) and STAT6 inhibition. The Company has two clinical-stage product candidates for RSV, which are zelicapavir and EDP-323. Glecaprevir, a protease inhibitor discovered by the Company, is part of one of the treatment regimens for curing chronic hepatitis c virus (HCV) infection and is sold by AbbVie in various countries under the tradenames MAVYRET (U.S.) and MAVIRET (ex-U.S.) (glecaprevir/pibrentasvir). The Company also has development programs in virology for SARS-CoV-2 and Hepatitis B virus.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q2

FY2026Q1

FY2025Q4

15.13M

+1.38%

-0.950

-10.38%

16.53M

-2.53%

-1.020

-2.86%

15.97M

+9.34%

-1.014

-25.44%

Estimates Revision

The market is revising Upward the revenue expectations for Enanta Pharmaceuticals, Inc. (ENTA) for FY2025, with the revenue forecasts being adjusted by 4.91% over the past three months. During the same period, the stock price has changed by 52.39%.

Revenue Estimates for FY2025

Revise Upward

+4.91%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-9.01%

In Past 3 Month

Stock Price

Go Up

+52.39%

In Past 3 Month

6 Analyst Rating

69.41% Upside

Wall Street analysts forecast ENTA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ENTA is 18.33 USD with a low forecast of 9.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

1 Hold

0 Sell

Strong Buy

69.41% Upside

Current: 10.820

Low

9.00

Averages

18.33

High

25.00

69.41% Upside

Current: 10.820

Low

9.00

Averages

18.33

High

25.00

Jefferies

Akash Tewari

Hold

Buy

upgrade

$14 -> $20

2025-10-01

Reason

Jefferies

Akash Tewari

Price Target

$14 -> $20

2025-10-01

upgrade

Hold

Buy

Reason

Jefferies analyst Akash Tewari upgraded Enanta to Buy from Hold with a price target of $20, up from $14.

Jefferies

Hold

Buy

upgrade

$14 -> $20

2025-10-01

Reason

Jefferies

Price Target

$14 -> $20

2025-10-01

upgrade

Hold

Buy

Reason

As previously reported, Jefferies upgraded Enanta to Buy from Hold with a price target of $20, up from $14, based on increased confidence that the company's RSV antiviral zalicapavir could become the first outpatient antiviral approved for RSV. While acknowledging that this week's Phase 2b RSV data in high-risk adults missed its primary endpoint, the firm argues that zalicapavir showed a "compelling signal" of about 3-7 days faster symptom resolution in a prespecified subgroup. The firm also thinks Enanta's early-stage oral drugs targeting KIT and STAT6 "could get more interesting over time," the analyst tells investors.

WestPark Capital

NULL -> Buy

initiated

$24

2025-09-02

Reason

WestPark Capital

Price Target

$24

2025-09-02

initiated

NULL -> Buy

Reason

WestPark Capital initiated coverage of Enanta with a Buy rating and $24 price target.

Citizens JMP

Outperform

maintain

$24 -> $25

2025-08-12

Reason

Citizens JMP

Price Target

$24 -> $25

2025-08-12

maintain

Outperform

Reason

Citizens JMP raised the firm's price target on Enanta to $25 from $24 and keeps an Outperform rating on the shares. Enanta Pharmaceuticals expects cash and continuing Mavyret income to fund operations into fiscal 2028, the analyst tells investors in a research note.

H.C. Wainwright

Brandon Folkes

initiated

$20

2025-07-28

Reason

H.C. Wainwright

Brandon Folkes

Price Target

$20

2025-07-28

initiated

Reason

H.C. Wainwright analyst Brandon Folkes assumed coverage of Enanta with a Buy rating and $20 price target. The shares offer a favorable risk/reward at current share levels, driven by the company's upcoming clinical catalysts and diversified pipeline in virology and immunology, the analyst tells investors in a research note. The firm likes the stock into the respiratory syncytial virus Phase 2 data readout.

Citizens JMP

Roy Buchanan

Outperform

maintain

$23 -> $24

2025-06-03

Reason

Citizens JMP

Roy Buchanan

Price Target

$23 -> $24

2025-06-03

maintain

Outperform

Reason

Citizens JMP analyst Roy Buchanan raised the firm's price target on Enanta to $24 from $23 and keeps an Outperform rating on the shares. Enanta remains on track to report Phase 2 results for oral RSV therapeutic candidate zelicapavir in Q3, but has indicated that further development of it and RSV-polymerase inhibitor EDP-323 will be dependent on a partner, the analyst tells investors in a research note. The firm has removed RSV from its valuation.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Enanta Pharmaceuticals Inc (ENTA.O) is -2.82, compared to its 5-year average forward P/E of 0.66. For a more detailed relative valuation and DCF analysis to assess Enanta Pharmaceuticals Inc 's fair value, click here.

Forward PE
Forward EV/EBITDA
Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

0.66

Current PE

-2.82

Overvalued PE

24.37

Undervalued PE

-23.06

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-10.79

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

10.35

Undervalued EV/EBITDA

-31.92

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

6.87

Current PS

10.96

Overvalued PS

11.40

Undervalued PS

2.33

Financials

Annual

Quarterly

FY2025Q3

YoY :

+1.91%

18.31M

Total Revenue

FY2025Q3

YoY :

-21.88%

-18.89M

Operating Profit

FY2025Q3

YoY :

-19.43%

-18.26M

Net Income after Tax

FY2025Q3

YoY :

-20.56%

-0.85

EPS - Diluted

FY2025Q3

YoY :

-181.40%

17.35M

Free Cash Flow

FY2025Q3

YoY :

0.00%

100.00

Gross Profit Margin - %

FY2025Q3

YoY :

-51.78%

-67.23

FCF Margin - %

FY2025Q3

YoY :

-20.94%

-99.68

Net Margin - %

FY2025Q3

N/A

ROIC

Trading Trends

Insider
Hedge Fund
Congress Trading

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

127.0K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

256.1K

USD

Months

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 137.44% over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

1.0M

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

127.0K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

256.1K

USD

Months

ENTA News & Events

Events Timeline

2025-09-30 (ET)

2025-09-30

21:17:29

Enanta's 6.5 Million Share Spot Secondary Offering Set at $10.00

2025-09-30

16:18:05

Enanta Launches $50M Secondary Offering; Price Set Between $10.00 and $10.50

2025-09-30

16:14:48

Enanta reveals $50 million common stock sale

News

9.0

10-20Newsfilter

Enanta Pharmaceuticals Unveils Latest Findings on Zelicapavir and EDP-323, Its N-Protein and L-Protein Inhibitors for Respiratory Syncytial Virus (RSV) Treatment, at IDWeek™ 2025

8.5

10-02Yahoo Finance

Enanta Pharmaceuticals Completes Stock Offering

4.0

10-01Benzinga

Jefferies Boosts Enanta Pharma Rating to Buy and Increases Price Target to $20